No Data
Brii Biosciences Says Data From Phase 2 Trial of Anti-Hepatitis B Drug 'Encouraging'
BRII-B (02137.HK) announced its ongoing Phase 2 ENSURE study data in the form of the latest breakthrough poster at the 2025 EASL conference.
Globe Union reported on May 8 that BRII-B (02137.HK) announced that it presented its ongoing Phase II ENSURE study data in the form of a latest breakthrough poster at the 2025 European Association for the Study of the Liver (EASL) meeting held in Amsterdam, Netherlands. ENSURE (NCT05970289) is a multi-center, open-label Phase II study. Cohorts 1-3 aim to evaluate elebsiran, an investigational small interfering RNA ("siRNA"), in combination with pegylated interferon alpha ("PEG-IFNα") for treating baseline hepatitis B.
BRII-B: 2024 Annual Report
Hong Kong stocks have fluctuated | The Innovative Drugs Concept has seen significant gains. Institutions state that there is no need to pay tariffs on the licensing fees for Innovative Drugs, and support policies for Innovative Drugs are expected to be gr
The Innovative Drugs Concept has seen significant growth, as of the time of reporting, LAEKNA-B (02105) is up 13.16%, priced at 12.04 Hong Kong dollars; BRII-B (02137) is up 12.35%, priced at 1.82 Hong Kong dollars; CSTONE PHARMA-B (02616) is up 10.88%, priced at 2.65 Hong Kong dollars; BEIGENE (06160) is up 8.27%, priced at 148 Hong Kong dollars; HBM HOLDINGS-B (02142) is up 7.41%, priced at 7.68 Hong Kong dollars.
BRII-B (02137.HK) spent 2.2596 million Hong Kong dollars to repurchase 1.4105 million shares on April 9.
Gelonghui April 9丨BRII-B (02137.HK) announced that on April 9, 2025, it spent 2.2596 million Hong Kong dollars to repurchase 1.4105 million shares, with the repurchase price per share ranging from 1.53 to 1.65 Hong Kong dollars.
On April 7, BRII-B (02137.HK) spent 8.41 million HKD to repurchase 5.31 million shares.
Gelonghui reported on April 7 that BRII-B (02137.HK) announced the repurchase of 5.31 million shares at a cost of 8.41 million Hong Kong dollars on April 7.
